Patrick Hwu: How can we overcome resistance to CAR T-cell therapy in R/R large B-cell lymphoma?
Patrick Hwu, President and CEO of Moffitt Cancer Center, shared a post on LinkedIn about a paper by Jakub Svoboda et al. published in NEJM:
“How can we overcome resistance to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma?
In this Phase I study, Carl June et. al tested huCART19-IL18 – CAR T cells engineered to secrete the immune-stimulating cytokine IL-18 – in patients who had already failed previous CAR T therapies. The response rate was 81%, with 52% of patients achieving complete remission at 3 months.
These specially designed CAR T cells are sometimes called “armored” because they’re enhanced to better activate the immune system and persist in the body. In this trial, they also benefited from a faster, 3-day manufacturing process. As cell therapies evolve, this kind of innovation could open the door to more durable responses – and second chances – for patients who previously had few.”
Title: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
Authors: Jakub Svoboda, Daniel J. Landsburg, James Gerson, Sunita D. Nasta, Stefan K. Barta, Elise A. Chong, Michael Cook, Noelle V. Frey, Joanne Shea, Amanda Cervini, Amy Marshall, Megan Four, Megan M. Davis, Julie K. Jadlowsky, Anne Chew, Edward Pequignot, Vanessa Gonzalez, Julia Han Noll, Luca Paruzzo, Juliana Rojas-Levine, Gabriela Plesa, John Scholler, Donald L. Siegel, Bruce L. Levine, David L. Porter, Saba Ghassemi, Marco Ruella, Andrew Rech, Rachel M. Leskowitz, Joseph A. Fraietta, Wei-Ting Hwang, Elizabeth Hexner, Stephen J. Schuster, Carl H. June
Read the Full Article in NEJM.
More posts featuring Patrick Hwu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023